A new diagnostic platform is able to screen for and identify four different diseases—colorectal cancer, glioblastoma, pancreatic cancer and Alzheimer’s disease—with a small amount of blood in an hour. The patent-pending technology was developed by a team of researchers led by Hsueh-Chia Chang at the University of Notre Dame.
The diagnostic platform was tested in a blind setting using 87 plasma samples from blood draws from patients who were either healthy or had one of the four diseases. The platform was found to be 90% to 99% accurate for detecting the presence or absence of each disease type.
“We believe that if we can screen these diseases earlier, then patients may have a better chance at surviving,” said Chang, the Bayer Corporation professor of engineering in the Department of Chemical and Biomolecular Engineering at Notre Dame. The study is published in Nature Biomedical Engineering.
